Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion

NCT01518881 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Stopped Corporate decision to reformulate the investigational product.

Conditions

Ebola Virus Infection

Interventions

DRUG: TKM-100201
DRUG: Placebo

Sponsor

Arbutus Biopharma Corporation

Collaborators

[object Object]